Dupilumab treatment restores lesional and nonlesional skin barrier function in adults and adolescents with atopic dermatitis irrespective of the filaggrin genotype: Results from an open-label, healthy-control-matched, phase 4 clinical study (BALISTAD).
Saved in:
| Title: | Dupilumab treatment restores lesional and nonlesional skin barrier function in adults and adolescents with atopic dermatitis irrespective of the filaggrin genotype: Results from an open-label, healthy-control-matched, phase 4 clinical study (BALISTAD). |
|---|---|
| Authors: | Bissonnette R; Innovaderm Research, Montreal, Quebec, Canada., Goleva E; National Jewish Health, Denver, Colorado., Berdyshev E; National Jewish Health, Denver, Colorado., Garcia S; National Jewish Health, Denver, Colorado., Ramirez-Gama M; National Jewish Health, Denver, Colorado., Taylor PA; National Jewish Health, Denver, Colorado., Bologna G; Ividata Life Sciences, Contractor for Sanofi, Chilly-Mazarin, France., Praestgaard AH; Sanofi, Cambridge, Massachusetts., Chen L; Regeneron Pharmaceuticals Inc., Tarrytown, New York., Levit NA; Dermatology Physicians of Connecticut, Fairfield, Connecticut., Zahn J; Regeneron Pharmaceuticals Inc., Tarrytown, New York., Rossi AB; Sanofi, Cambridge, Massachusetts., Zhang A; Sanofi, Cambridge, Massachusetts., Leung DYM; National Jewish Health, Denver, Colorado. Electronic address: LeungD@NJHealth.org. |
| Source: | Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2025 May; Vol. 92 (5), pp. 1132-1136. Date of Electronic Publication: 2025 Jan 22. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Mosby Country of Publication: United States NLM ID: 7907132 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-6787 (Electronic) Linking ISSN: 01909622 NLM ISO Abbreviation: J Am Acad Dermatol Subsets: MEDLINE; In Process |
| Database: | MEDLINE Ultimate |
| ISSN: | 1097-6787 |
|---|---|
| DOI: | 10.1016/j.jaad.2024.11.079 |
